Therefore, targeting of the BCL2 protein family is entering an exciting new era, and multiple new applications for modulating the activity of BCL2 proteins selectively in diseased tissues are foreseeable even beyond the treatment of cancer. The gene discussed is BCL2; the disease is cancer.